药明生物(02269)今日盘中大涨5.21%,引发市场广泛关注。公司发布的数据显示,2024年新增综合项目151个,项目总数达817个,创下历史新高,体现了公司业务势头强劲和持续增长能力。
值得一提的是,药明生物基于现有合同预期,2025年将迎来24个PPQ(工艺性能确认)项目。同时,公司位于爱尔兰的生产设施也将如期于2025年实现盈利。这意味着公司在未来一年的业绩有望进一步向好。
对此,券商机构纷纷作出乐观预期。里昂证券在最新研报中上调了对药明生物2024年至2026年收入及净利润的预测,目标价由22.6港元上调至22.9港元,并重申"跑赢大市"评级。市场对于药明生物未来的发展前景充满期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.